NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, ...

Pfizer Inc. (NYSE:PFE – Get Free Report ... and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

In this article, we will look at the 10 Best Performing Pharma Stocks So Far in 2025. What’s Going on in the Pharma Sector?

Pfizer's reported interest in acquiring sickle ... and made an $11.6 billion takeover bid for Biohaven and its migraine therapy Nurtec ODT (rimegepant).

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...